CADTH

CADTH REIMBURSEMENT REVIEW

Stakeholder Feedback on Draft Recommendation

Empagliflozin (Jardiance)

(Boehringer Ingelheim (Canada) Ltd.)

Indication: Heart failure.

September 29, 2022

CADTH

CADTH Reimbursement Review

Feedback on Draft Recommendation

Stakeholder information	
CADTH project number	SR0726
Name of the drug and Indication(s)	Empagliflozin (Jardiance) indicated in adults, as an adjunct to standard of care therapy for the treatment of chronic heart failure
Organization Providing Feedback	FWG

1. Recommendation revisions Please indicate if the stakeholder requires the expert review committee to reconsider or clarify its recommendation.		
Request for Reconsideration	**Major revisions:** A change in recommendation **category** or patient **population** is requested	☐
	Minor revisions: A change in reimbursement **conditions** is requested	☐
No Request for Reconsideration	**Editorial revisions:** Clarifications in recommendation **text** are requested	X
	No requested revisions	☐

2. Change in recommendation category or conditions Complete this section if major or minor revisions are requested
Please identify the specific text from the recommendation and provide a rationale for requesting a change in recommendation.

3. Clarity of the recommendation Complete this section if editorial revisions are requested for the following elements
a) Recommendation rationale
1) Please clarify the cost condition, in that the incremental cost is related to jardiance alone, as standard of therapy is currently funded. 2) It would be helpful if the requirement for patients to be on standard therapies of BB+ACE/ARB/ARNI+MRA was included in the reimbursement conditions. 3) Further clarity around the price comparison between empagliflozin and dapagliflozin should be provided, potentially in a discussion point, as the empagliflozin is broader and includes patients with both preserved and reduced ejection fraction. Please provide details regarding the information that requires clarification.

b) Reimbursement conditions and related reasons
Please provide details regarding the information that requires clarification.
c) Implementation guidance
Please provide high-level details regarding the information that requires clarification. You can provide specific comments in the draft recommendation found in the next section. Additional implementation questions can be raised here.